Michael J. Crescenz

Combinatorial Pharmacogenomic Testing Improves Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized, Controlled Trial

Objectives: The GUIDED trial demonstrated that combinatorial pharmacogenomic (PGx) testing significantly improved the rate of response (p=0.007) and remission (p=0.005) and approached sig...

John Greden , MD;

Anthony Rothschild , MD;

Michael Thase , MD;

Boadie Dunlop , MD;

Richard Shelton , MD;

Charles Conway , MD;

Lisa Brown , PhD;

Jennie Depatie , PhD;

Brent Forester , MD, MSc;

James Li , MS, PhD;

Matthew Macaluso , DO;

Krystal Brown , PhD;

Michael J. Crescenz ;

Michael Jablonski , PhD;

Charles DeBattista , MD;

Sagar Parikh , MD;

11/22/2019

An Experimental Study to Assess the Professional and Social Consequences of Mild-to-Moderate Tardive Dyskinesia

BACKGROUND: Tardive dyskinesia (TD), a movement disorder, may arise in patients taking antipsychotics. Social and professional stigma associated with mild-to-moderate TD movements has not...

Stanley Caroff , MD;

Benjamin Carroll , PharmD;

Debbie Goldschmidt , PhD;

Fan Mu , PhD;

Michael J. Crescenz ;

Rajeev Ayyagari , PhD;

11/22/2019